Clinical Research Directory

Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)

This is a Phase II, single-arm, Bayesian adaptive trial. The study employs a two-stage design with an interim analysis after 30 evaluable patients and a maximum enrolment of 60 patients. T-DXd is administered at 5.4 mg/kg intravenously every 3 weeks until intracranial or systemic progression, unacceptable toxicity, or patient withdrawal. SRS (single-fraction) or fractionated stereotactic radiotherapy (fSRT, 3-5 fractions) is delivered within 21 days of enrolment, before Cycle 1 (with a minimum interval of 10 days from local treatment completion and Cycle 1 of T-DXd and a maximum interval of 28 days), for patients with 1-10 BMs and cumulative planning target volume ≤ 20.0 mL.

Blood Biomarkers for Breast Cancer Treatment Response

This study looks at whether a simple blood test can help predict how well a breast cancer treatment will work. It follows patients with advanced hormone receptor-positive breast cancer whose cancer has progressed after their first treatment. Researchers collect a blood sample when patients start a second hormone therapy treatment and may collect additional samples over time. By comparing blood test results with patient outcomes, the study aims to identify biomarkers that can predict which patients are most likely to benefit from treatment.

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1,TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.